Jump to content

ICI-164384: Difference between revisions

Edit links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
ChEBI ID added to CHEMBOX identifiers
→External links: link currently works
 
(3 intermediate revisions by 3 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{Drugbox
{{Drugbox
| Verifiedfields =
| Verifiedfields =
Line 65: Line 66:


==External links==
==External links==
* [http://webcache.googleusercontent.com/search?q=cache:1BnQZCqpGc4J:adisinsight.springer.com/drugs/800000792+&cd=1&hl=en&ct=clnk&gl=us ICI-164384 - AdisInsight]{{dead link|date=April 2017 |bot=InternetArchiveBot |fix-attempted=yes }}
* [http://adisinsight.springer.com/drugs/800000792 ICI-164384 - AdisInsight]


{{Estrogen receptor modulators}}
{{Estrogen receptor modulators}}


[[Category:Antiestrogens]]
[[Category:Antiestrogens]]
[[Category:AstraZeneca brands]]
[[Category:Drugs developed by AstraZeneca]]
[[Category:Carboxamides]]
[[Category:Carboxamides]]
[[Category:Diols]]
[[Category:Diols]]

Latest revision as of 15:38, 1 March 2024

ICI-164384
Clinical data
Other namesN-n-Butyl-N-methyl-11-(3,17β-dihydroxyestra-1,3,5(10)-trien-7α-yl)undecanamide
Identifiers
  • N-butyl-11-[(7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-7-yl]-N-methylundecanamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC34H55NO3
Molar mass525.818 g·mol−1
3D model (JSmol)
  • CCCCN(C)C(=O)CCCCCCCCCC[C@@H]1CC2=C(C=CC(=C2)O)[C@@H]3[C@@H]1[C@@H]4CC[C@@H]([C@]4(CC3)C)O
  • InChI=1S/C34H55NO3/c1-4-5-22-35(3)32(38)15-13-11-9-7-6-8-10-12-14-25-23-26-24-27(36)16-17-28(26)29-20-21-34(2)30(33(25)29)18-19-31(34)37/h16-17,24-25,29-31,33,36-37H,4-15,18-23H2,1-3H3/t25-,29-,30+,31+,33-,34+/m1/s1
  • Key:BVVFOLSZMQVDKV-KXQIQQEYSA-N

ICI-164384, also known as N-n-butyl-N-methyl-11-(3,17β-dihydroxyestra-1,3,5(10)-trien-7α-yl)undecanamide, is a steroidal antiestrogen and a synthetic derivative of estradiol which is closely related to fulvestrant and was never marketed.[1][2] It is a silent antagonist of the estrogen receptor (ER) with no intrinsic estrogenic activity and hence is a pure antiestrogen, unlike selective estrogen receptor modulators (SERMs) like tamoxifen.[1][2] The drug was under development by AstraZeneca for the treatment of breast cancer but was discontinued in favor of fulvestrant,[3] which is very similar to ICI-164384 but is more potent in comparison.[4]

See also

[edit]

References

[edit]
  1. ^ a b Pavlik EJ (6 December 2012). Estrogens, Progestins, and Their Antagonists: Health Issues. Springer Science & Business Media. pp. 133–. ISBN 978-1-4612-4096-9.
  2. ^ a b Howell A (15 October 1990). The Role of Antihormones. CRC Press. pp. 119–124. ISBN 978-1-85070-295-5.
  3. ^ "ICI 164384". AdisInsight. Springer Nature Switzerland AG.
  4. ^ Miller WR, Ingle JN (8 March 2002). Endocrine Therapy in Breast Cancer. CRC Press. pp. 64–. ISBN 978-0-203-90983-6.
[edit]
Stub icon

This article about a steroid is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=ICI-164384&oldid=1211245248"